Rapidly produced SAM ® vaccine against H7N9 influenza is immunogenic in mice

Emerging Microbes and Infections

Volumn 2, Issue , 2013, Pages

  Hekele, Armin ^a   Bertholet, Sylvie ^b   Archer, Jacob ^a   Gibson, Daniel G ^c   Palladino, Giuseppe ^a   Brito, Luis A ^a   Otten, Gillis R ^a   Brazzoli, Michela ^b   Buccato, Scilla ^b   Bonci, Alessandra ^b   Casini, Daniele ^b   Maione, Domenico ^b   Qi, Zhi Qing ^c   Gill, John E ^c   Caiazza, Nicky C ^c   Urano, Jun ^c   Hubby, Bolyn ^c   Gao, George F ^d   Shu, Yuelong ^d   De Gregorio, Ennio ^d   Mandl, Christian W ^b   Mason, Peter W ^a   Settembre, Ethan C ^a   Ulmer, Jeffrey B ^a   Craig Venter, J ^c   Dormitzer, Philip R ^a   Rappuoli, Rino ^b   Geall, Andrew J ^a   more..

^a Clinical Research and Development   (United States)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^c Synthetic Genomics Inc   (United States)

^d CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTINATION INHIBITING ANTIBODY; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; NEUTRALIZING ANTIBODY; SAM; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIRUS SIALIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; FEMALE; GENE SYNTHESIS; HEMAGGLUTINATION INHIBITION TEST; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA A; INFLUENZA A (H7N9); INFLUENZA VACCINATION; INFLUENZA VIRUS A; INFLUENZA VIRUS A H7N9; MOUSE; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; VIRUS NEUTRALIZATION;

EID: 84883230210     PISSN: None     EISSN: 22221751     Source Type: Journal    
DOI: 10.1038/emi.2013.54     Document Type: Article

References (31)

1. Rappuoli R, Dormitzer PR. Influenza: options to improve pandemic preparation. Science 2012; 336: 1531-1533.
2. Gao R, Cao B, Hu Y et al. Human infectionwith a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013; 368: 1888-1897.
3. Dawood FS, Iuliano AD, Reed C et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis 2012; 12: 687-695.
4. New influenza A (H1N1) virus: global epidemiological situation, June 2009. Wkly Epidemiol Rec 2009; 84: 249-257.
5. Abelin A, Colegate T, Gardner S, Hehme N, Palache A. Lessons from pandemic influenza A(H1N1): the research-based vaccine industry's perspective. Vaccine 2011; 29: 1135-1138.
6. Neumann G, Kawaoka Y. The first influenza pandemic of the new millennium. Influenza Other Respi Viruses 2011; 5: 157-166.
7. Tizzoni M, Bajardi P, Poletto C et al. Real-time numerical forecast of global epidemic spreading: case study of 2009 A/H1N1pdm. BMC Med 2012; 10: 165.
8. Dormitzer PR, Tsai TF, del Giudice G. New technologies for influenza vaccines. Hum Vaccin Immunother 2012; 8: 45-58.
9. Mooney AJ, Tompkins SM. Experimental vaccines against potentially pandemic and highly pathogenic avian influenza viruses. Future Virol 2013; 8: 25-41.
10. Petsch B, Schnee M, Vogel AB et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat Biotechnol 2012; 30: 1210-1216.
11. Dormitzer PR, Suphaphiphat P, Gibson DG et al. Synthetic generation of influenza vaccine viruses for rapid response to pandemics. Sci Transl Med 2013; 5:185ra168.
12. Lalor PA, Webby RJ, Morrow J et al. Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. J Infect Dis 2008; 197: 1643-1652. (Pubitemid 351919627)
13. Ledgerwood JE, Wei CJ, Hu Z et al. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis 2011; 11: 916-924.
14. Geall AJ, Verma A, Otten GR et al. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci USA 2012; 109: 14604-14609.
15. Pascolo S. Vaccination with messenger RNA (mRNA). Handb Exp Pharmacol 2008; (183): 221-235.
16. Perri S, Greer CE, Thudium K et al. An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector. J Virol 2003; 77: 10394-10403. (Pubitemid 37129683)
17. Heyes J, Palmer L, Bremner K, MacLachlan I. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J Control Release 2005; 107: 276-287. (Pubitemid 41316290)
18. Dormitzer PR, Rappuoli R, Casini D et al. Adjuvant is necessary for a robust immune response to a single dose of H1N1 pandemic flu vaccine in mice. PLoS Curr 2009; 1: RRN1025.
19. Brito LA, Chan M, Baudner B et al. An alternative renewable source of squalene for use in emulsion adjuvants. Vaccine 2011; 29: 6262-6268.
20. de Jong JC, Palache AM, Beyer WE, Rimmelzwaan GF, Boon AC, Osterhaus AD. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 2003; 115: 63-73.
21. Chen Y, Liang W, Yang S et al. Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome. Lancet 2013; 381: 1916-1925.
22. Dowdle WR, Coleman MT, Mostow SR, Kaye HS, Schoenbaum SC. Inactivated influenza vaccines. 2. Laboratory indices of protection. Postgrad Med J 1973; 49: 159-163.
23. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008; 47: 401-409.
24. Black S, Nicolay U, Vesikari T et al. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J 2011; 30: 1081-1085.
25. Fleeton MN, Chen M, Berglund P et al. Self-replicative RNA vaccines elicit protection against influenza A virus, respiratory syncytial virus, and a tickborne encephalitis virus. J Infect Dis 2001; 183: 1395-1398. (Pubitemid 32337123)
26. Cai Y, Rodriguez S, Hebel H. DNA vaccine manufacture: scale and quality. Expert Rev Vaccines 2009; 8: 1277-1291.
27. Gill P, Ghaemi A. Nucleic acid isothermal amplification technologies: a review. Nucleosides Nucleotides Nucleic Acids 2008; 27: 224-243. (Pubitemid 351220650)
28. Ulmer JB, Mason PW, Geall A, Mandl CW. RNA-based vaccines. Vaccine 2012; 30: 4414-4418.
29. Geall AJ, Mandl CW, Ulmer JB. RNA: The new revolution in nucleic acid vaccines. Semin Immunol 2013 June 1. doi:10.1016/j.smim.2013.05.001.
30. Pascolo S. Messenger RNA-based vaccines. Expert Opin Biol Ther 2004; 4: 1285-1294. (Pubitemid 39005734)
31. Jones KL, Drane D, Gowans EJ. Long-term storage of DNA-free RNA for use in vaccine studies. Biotechniques 2007; 43: 675-681. (Pubitemid 350174918)